公开(公告)号：US20150037328A1

公开(公告)日：2015-02-05

申请号：US14449478

申请日：2014-08-01

Applicant: Pfizer Inc.

Inventor： Shu-Hui LIU ,  Flavia Mercer PERNASETTI ,  Wei-Hsien HO

IPC: C07K16/28 ,  A61K47/48

CPC classification number: C07K16/2866 ,  A61K39/3955 ,  A61K47/6803 ,  A61K47/6809 ,  A61K47/6847 ,  A61K47/6849 ,  A61K47/6851 ,  A61K49/0002 ,  A61K2039/505 ,  C07H21/04 ,  C07K14/7158 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  C12N15/09

Abstract: The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.

Abstract translation: 本发明提供结合趋化因子受体4（CXCR4）的抗体和相关分子。 本发明进一步提供包含此类抗体的抗体 - 药物偶联物，编码抗体的核酸，以及获得此类抗体的方法。 本发明还涉及使用这些抗体和抗CXCR4抗体 - 药物偶联物治疗与CXCR4功能或表达相关的疾病（例如癌症）如结肠，RCC，食管癌，胃癌，头部和/ 颈，肺，卵巢，胰腺癌或血液癌。